Showing results (21-30 of 307) with videos related to
Sort By:
Pageof 31
Clinical Parkinsonism & Related Disorders|December 10, 2021
AbobotulinumtoxinA provides flexibility for the treatment of cervical dystonia with 500 U/1 mL and 500 U/2 mL dilutionsMark F Lew, Robert A Hauser, Stuart H Isaacson, et al.Parkinsonism & Related Disorders|May 29, 2020
Clinical implications of gastric complications on levodopa treatment in Parkinson's diseaseRonald F Pfeiffer, Stuart H Isaacson, Rajesh PahwaNeuropsychiatric Disease and Treatment|October 27, 2021
Tardive Dyskinesia in Older Persons Taking AntipsychoticsLeslie Citrome, Stuart H Isaacson, Danielle Larson, et al.Clinical Parkinsonism & Related Disorders|July 16, 2024
Corrigendum to "Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease" [Clin. Parkinsonism Related Dis. 9 (2023) 100223]Bruno Bergmans, Veronica Clark, Stuart H Isaacson, et al.Clinical Parkinsonism & Related Disorders|November 29, 2023
Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's diseaseBruno Bergmans, Veronica Clark, Stuart H Isaacson, et al.Clinical Parkinsonism & Related Disorders|March 25, 2022
Efficacy and safety of two incobotulinumtoxinA injection intervals in cervical dystonia patients with inadequate benefit from standard injection intervals of botulinum toxin: Phase 4, open-label, randomized, noninferiority studyCynthia Comella, Robert A Hauser, Stuart H Isaacson, et al.Journal of Parkinson'S Disease|July 28, 2020
Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease PsychosisStuart H Isaacson, Bruce Coate, James Norton, et al.Expert Review of Neurotherapeutics|February 1, 2012
IPX066: a novel carbidopa-levodopa extended-release formulationRobert A HauserPageof 31